Table 1.

Description of patient population^a

Group	IV Busulfan	Oral Busulfan
N	57	95
Age (years)
Mean ± standard deviation (SD)	38 ± 21	45 ± 12
N < 18 years	13	1
AIBW (kg)
Mean ± SD	58 ± 25	66 ± 10
N < 12 kgb	8b	0
Body mass indexc (kg/m2)
Mean	27 ± 6.9	27 ± 5.7
Underweight	8 (14%)	0
Normal (18.5–24.9)	22 (39%)	34 (36%)
Overweight (25.0–29.9)	18 (32%)	30 (32%)
Obesity I (30.0–34.9)	5 (9%)	21 (22%)
Obesity II (35.0–39.9)	1 (2%)	7 (7%)
Extreme Obesity (40.0+)	3 (5%)	3 (3%)
Ethnic background
Caucasian	46 (81%)	76 (80%)
Asian	2 (4%)	6 (6%)
African American	1 (2%)	5 (5%)
East Indian	1 (2%)	3 (3%)
Hispanic	1 (2%)	2 (2%)
Native American	1 (2%)	2 (2%)
Unknown	5 (9%)	1 (1%)
Gender
Male	34 (60%)	48 (51%)
Female	23 (40%)	47 (49%)
Conditioning Regimen
Busulfan + Flu ± THY	39 (68%)	0
Busulfan + CY ± THY ± etoposide	15 (26%)	94 (98%)
Busulfan + Flu + CY	2 (4%)	1
Busulfan + melphalan	1 (2%)	0
Diagnosis
Myelodysplastic syndrome	17 (30%)	27 (28.4%)
Acute myeloid leukemia	13 (23%)	29 (30.5%)
Acute myeloid leukemia/myelodysplastic syndrome	0	6 (6.3%)
Myelofibrosis	6 (11%)	9 (9.5%)
Chronic myelomonocytic leukemia	5 (9%)	0
Wiskott-Aldrich syndrome	3 (5%)	0
Osteopetrosis	3 (5%)	0
Chronic myeloid leukemia	2 (4%)	16 (16.9%)
Hemophagocytic lymphohistiocytosis	2 (4%)	0
Agnogenic myeloid metaplasia	1 (2%)	0
Multiple myeloma	1 (2%)	0
Blackfan-Diamond anemia	1 (2%)	0
Congenital dyserythropoietic	1 (2%)	0
Sickle cell anemia	1 (2%)	0
β-Thalassemia	1 (2%)	0

^aData presented as N or mean ± standard deviation;

^bwithin the package insert, children less than 12 kg should receive a higher initial busulfan dose than heavier children and adults;

^ccategorized per National Heart Lung and Blood Institute